HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time
August 16, 2019
-
TRENDS Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
-
BUSINESS Sumitomo Dainippon Going Full Tilt for Napabucasin Colorectal Cancer Trial after Pancreatic Flop
August 8, 2019
-
BUSINESS Novartis’ Entresto Filed in Japan for Chronic Heart Failure
August 7, 2019
-
BUSINESS Gearing Up for Japan Debut, Daiichi Sankyo Mounting Push for AML Med Vanflyta
August 6, 2019
-
REGULATORY MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
-
REGULATORY Tecentriq’s SCLC Use Gets MHLW Panel Nod for September Approval
August 5, 2019
-
REGULATORY MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
-
BUSINESS Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
-
BUSINESS Crushing Defeat or Sign of Hope? Analyst, KOL Give Mixed Views for CheckMate-227
July 31, 2019
-
BUSINESS Mitsubishi Tanabe’s Sales Fall 6.9% as Gilenya Snafu Takes Toll
July 30, 2019
-
BUSINESS Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
-
BUSINESS Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
-
REGULATORY Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
-
BUSINESS Ayumi to Ease Restrictions on Enbrel Biosimilar Use as Product Boost Progresses
July 24, 2019
-
REGULATORY 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
-
BUSINESS Boehringer Said to Consider Nixing Allowances for Some Wholesalers, Denies Intention to Narrow Distributors
July 23, 2019
-
REGULATORY MHLW Panel to Review Tecentriq’s SCLC Use and More for September OK
July 23, 2019
-
BUSINESS Nitto Pharma Accelerating Development of Gut Bacteria Drugs, Eyes Clinical Studies within 3 Years
July 22, 2019
-
ORGANIZATION Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
